Drug Profile
SPI 256
Alternative Names: SPI-256Latest Information Update: 11 May 2011
Price :
$50
*
At a glance
- Originator Sequoia Pharmaceuticals
- Class Antiretrovirals; Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 29 Oct 2008 Final pharmacokinetic and adverse events data from a phase I trial in HIV infections presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America (ICAAC/IDSA-2008) ,.
- 30 Jun 2007 Phase-I clinical trials in HIV infections in USA (unspecified route)
- 28 Feb 2007 Sequoia Pharmaceuticals files an IND with the the US FDA for SPI 256